Document is current
Any future updates will be listed below
-
Authors
Borck, Patricia C.
Boyle, Isabella https://orcid.org/0000-0002-8138-1225
Jankovic, Kristina
Bick, Nolan https://orcid.org/0000-0001-8963-7304
Foster, Kyla
Lau, Anthony C.
Parker-Burns, Lucy I.
Lubicki, Daniel A.
Li, Tianxia
Borah, Ashir A.
Lofaso, Nicholas J. https://orcid.org/0009-0002-5065-0565
Das Sharma, Sohani
Chan, Tessla
Kishen, Riya V. https://orcid.org/0009-0000-3839-7267
Adeagbo, Anisah
Raghavan, Srivatsan https://orcid.org/0000-0002-5374-9918
Aquilanti, Elisa
Prensner, John R. https://orcid.org/0000-0002-7024-636X
Krill-Burger, J. Michael https://orcid.org/0000-0001-9614-4671
Golub, Todd R. https://orcid.org/0000-0003-0113-2403
Campbell, Catarina D.
Dempster, Joshua M. https://orcid.org/0000-0002-3634-9576
Chan, Edmond M. https://orcid.org/0000-0002-7460-2560
Vazquez, Francisca https://orcid.org/0000-0002-2857-4685
- License Information
-
More Information
Article History
Received: 27 April 2024
Accepted: 10 December 2024
First Online: 5 February 2025
Competing interests
: S.R. holds equity in Amgen and receives research funding from Microsoft. J.R.P. is a paid consultant for ProFound Therapeutics. T.R.G. receives research funding from Calico Life Sciences and Deerfield Management, is a founder and equity holder of Sherlock Biosciences and Amplifyer Bio, and serves as a paid consultant and equity holder of Anji Pharmaceuticals and Dewpoint Therapeutics. C.D.C. serves as a paid consultant for Droplet Biosciences. J.M.D. is a consultant for and owns equity in Jumble Therapeutics. E.M.C. serves as a paid consultant for AbbVie, receives research support from Novartis and Genentech, and has received research support from Bayer. F.V. receives research support from the Dependency Map Consortium, Riva Therapeutics, Bristol Myers Squibb, Merck, Illumina and Deerfield Management. F.V. is on the scientific advisory board of GSK, is a consultant for and holds equity in Riva Therapeutics, and is a cofounder of and holds equity in Jumble Therapeutics. The remaining authors declare no competing interests.
